Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy

Andrea Pession, Eveline Barbieri, Nicola Santoro, Paolo Paolucci, Fulvio Porta, Franco Locatelli

Research output: Contribution to journalArticle

Abstract

Rasburicase has been defined as a potent urolytic agent for management of malignancy-associated hyperuricemia. We reviewed the data of 26 children with malignancy at risk for TLS who received rasburicase for treatment or prophylaxis of acute hyperuricemia, producing a significant decrease in uric acid level in all the patients. Tolerance of treatment was excellent. Rasburicase is a safe, highly and rapidly effective agent in the treatment and prevention of malignancies-associated acute hyperuricemia.

Original languageEnglish
Pages (from-to)141-142
Number of pages2
JournalHaematologica
Volume90
Issue number1
Publication statusPublished - Jan 2005

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy'. Together they form a unique fingerprint.

  • Cite this